Comparison · NCT03028740-sae
Cenicriviroc 150 mg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cenicriviroc 150 mg vs Placebo: serious adverse events. Trial comparisons, record NCT03028740-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03028740-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.135 | 0.116 | 0.155 | wilson | |
| Risk in group 2 | 0.119 | 0.0951 | 0.147 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0159 | -0.0181 | 0.0473 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.13 | 0.871 | 1.48 | log | |
| Odds ratio, group 1 over group 2 | 1.15 | 0.855 | 1.56 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Cenicriviroc 150 mg than on Placebo | 62.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cenicriviroc 150 mg | Participants received cenicriviroc,150 mg, tablet, orally, once daily for up to approximately 40 months. | 159 | 1,180 | EG001 |
| Group 2 | Placebo | Participants received cenicriviroc placebo-matching, tablet, orally, once daily for up to approximately 40 months. | 70 | 589 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From first dose through 30 days after the last dose of study drug (Up to approximately 42 months)
Source ClinicalTrials.gov
Trial
- Title
- AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
- NCT number
- NCT03028740
- Phases
- PHASE3
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Placebo, Cenicriviroc
- Lead sponsor
- Tobira Therapeutics, Inc.
- Results first posted
- 2022-03-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03028740?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03028740-sae